Get the Weekly Intelligence Brief — top committee picks every Sunday.
ATR · NASDAQ · STOCK

AptarGroup

Healthcare Updated August 08, 2026
$135.46
52W $103.23 – $146.91
57/100
$8.64B
24.2
0.39
AI Committee Verdict
Buy
57/100
Conviction: Moderate · 60% agreement · 5 analysts
+0.2%
-2.8%
0.09:1
Moderate
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.

Is ATR Bullish or Bearish?

Bullish. Innellis AI committee rates AptarGroup (ATR) Buy with a composite score of 57/100 , based on 5 analysts with 60% agreement. Last updated August 08, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +17.70 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -2.30 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

Positive signals support the current rating — market regime is bullish (bull market -- normal position sizing). The committee sees sufficient evidence to maintain the constructive view.

Bull & Bear Case

Bull Case
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
  • News sentiment is positive (+0.20 across 16 articles, 14d) — News
Bear Case
  • EPS declining -4.4% YoY despite any revenue growth — Growth
  • 2 consecutive earnings misses -- execution concerns — Growth
  • MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 08, 2026
Overall Committee Score
57/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 68%
of 95 Healthcare peers
Value Analyst neutral
58 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
Growth Analyst neutral
41 / 100 · High confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− EPS declining -4.4% YoY despite any revenue growth
Technical Analyst neutral
54 / 100 · High confidence
Mixed or range-bound price action
+ Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement
− MACD histogram negative -- bearish momentum
Macro Analyst bullish
70 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
64 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 16 articles, 14d)
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 4 existing position pair(s) are highly correlated already
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 58.8 to 57.3.

Analyst-level changes:
  • News Analyst: +1 bullish signal(s).
  • Technical Analyst: stance bullish->neutral; score 61->54 (-8); +1 bearish signal(s).

Comparing 2026-08-07 to 2026-08-08 (1 day apart).

Technical Analysis

RSI (14)
58.1
Neutral
MACD Histogram
-0.084
Bearish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Lh Ll
Support
$131.74
Resistance
$135.79
Bollinger %B
0.69
Inside Bands
Price vs Moving Averages
EMA 9
$135.08 Above
EMA 21
$132.48 Above
EMA 50
$128.25 Above
EMA 200
$128.50 Above

Fundamental Analysis

Valuation
79
Growth
53
Profitability
54
Financial Health
83
Cash Flow
70
Valuation
P/E Ratio 24.2×
P/B Ratio 3.29×
PEG Ratio -4.61
Dividend Yield 1.42%
52W High $146.91
52W Low $103.23
Quality & Growth
ROE 1472.2%
ROA 747.8%
Gross Margin 2826.1%
Operating Margin 1237.0%
Revenue Growth YoY
Debt / Equity 0.54
AI Fundamental Assessment
P/E ratio of 24.2 (inexpensive relative to a 15-40x range); Price-to-book of 3.3x; PEG ratio of -4.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 14.7%; Return on assets of 7.5%; Net margin of 9.2%; Gross margin of 28.3%; Current ratio of 1.61 (healthy short-term liquidity); Debt-to-equity of 0.54; Free cash flow per share is positive (4.86); Most recent quarter missed estimates by 3.9%; 2 consecutive earnings misses; EPS growth accelerating (-4.8% -> +19.3% QoQ); Average YoY EPS growth of -14.5%; Analyst estimates rising over recent quarters
Get the Full ATR Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore ATR Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime